Targeting miRNA-based medicines to cystic fibrosis airway epithelial cells using nanotechnology

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 3907-3915

  McKiernan, Paul J ^b   Cunningham, Orla ^a,b   Greene, Catherine M ^b   Cryan, Sally Ann ^a,c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cystic fibrosis; High content analysis; Inflammation; MiR 126; Nanotechnology; TOM1

Indexed keywords

CHITOSAN; MICRORNA; MICRORNA 126; NANOPARTICLE; POLYETHYLENEIMINE;

ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOPLASM; DRUG CYTOTOXICITY; EPITHELIUM CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; NANOBIOTECHNOLOGY; NANOMEDICINE; PARTICLE SIZE; RESPIRATORY EPITHELIUM; SURFACE PROPERTY; ZETA POTENTIAL;

CYSTIC FIBROSIS; HIGH CONTENT ANALYSIS; INFLAMMATION; MIR-126; NANOTECHNOLOGY; TOM1;

CELL LINE; CYSTIC FIBROSIS; EPITHELIAL CELLS; GENETIC THERAPY; HUMANS; MICRORNAS; NANOCAPSULES; PARTICLE SIZE; RESPIRATORY MUCOSA;

EID: 84885737547     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S47551     Document Type: Article

References (41)

1. Oglesby IK, Bray IM, Chotirmall SH, et al. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol. 2010;184:1702-1709.
2. Rommens J, Kerem B, Alon N, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066-1073.
3. Sheridan MB, Hefferon TW, Wang N, et al. CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR. J Med Genet. 2011;48:235-241.
4. McNally P, Coughlan C, Bergsson G, et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros. 2011;10:428-434.
5. Cosgrove S, Chotirmall SH, Greene CM, McElvaney NG. Pulmonary proteases in the cystic fibrosis lung induce interleukin 8 expression from bronchial epithelial cells via a heme/meprin/epidermal growth factor receptor/Toll-like receptor pathway. J Biol Chem. 2011;286: 7692-7704.
6. Greene CM, Ramsay H, Wells RJ, O'Neill SJ, McElvaney NG. Inhibition of Toll-like receptor 2-mediated interleukin-8 production in cystic fibrosis airway epithelial cells via the alpha7-nicotinic acetylcholine receptor. Mediators Inflamm. 2010;2010:423241.
7. Chotirmall SH, Greene CM, Oglesby IK, et al. 17Beta-estradiol inhibits IL-8 in cystic fibrosis by up-regulating secretory leucoprotease inhibitor. Am J Respir Crit Care Med. 2010;182:62-72.
8. Bergin DA, Greene CM, Sterchi EE, et al. Activation of the epidermal growth factor receptor (EGFR) by a novel metalloprotease pathway. J Biol Chem. 2008;283:31736-31744.
9. Greene CM, Carroll TP, Smith SG, et al. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. J Immunol. 2005;174:1638-1646.
10. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 2007;8:23-36.
11. Oglesby IK, McElvaney NG, Greene CM. MicroRNAs in inflammatory lung disease-master regulators or target practice? Respir Res. 2010;11:148.
12. Bartel D. MicroRNAs genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
13. Bhattacharyya S, Balakathiresan NS, Dalgard C, et al. Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem. 2011;286:11604-11615.
14. Bazett M, Paun A, Haston CK. MicroRNA profiling of cystic fibrosis intestinal disease in mice. Mol Genet Metab. 2011;103:38-43.
15. Xu W, Hui C, Yu SS, Jing C, Chan HC. MicroRNAs and cystic fibrosis-an epigenetic perspective. Cell Biol Int. 2011;35:463-466.
16. Gillen AE, Gosalia N, Leir H, Harris A. MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem J. 2011;438:25-32.
17. Megiorni F, Cialfi S, Dominici C, Quattrucci S, Pizzuti A. Synergistic post-transcriptional regulation of the cystic fibrosis transmembrane conductance regulator (CFTR) by miR-101 and miR-494 specific binding. PLoS One. 2011;6:e26601.
18. Ramachandran S, Karp PH, Jiang P, et al. A microRNA network regulates expression and biosynthesis of wild-type and deltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A. 2012;109:13362-13367.
19. Hassan F, Nuovo GJ, Crawford M, et al. miR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One. 2012;7:e50837.
20. Oglesby IK, Chotirmall SH, McElvaney NG, Greene CM. Regulation of CFTR by microRNA-145, -223 and -494 is altered in ΔF508 cystic fibrosis airway epithelium. J Immunol. 2013;190:3354-3362.
21. Durcan N, Murphy C, Cryan S-A. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 2008;5:559-566.
22. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269.
23. Howard KA. Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv Drug Deliv Rev. 2009;61:710-720.
24. Guo P, Coban O, Snead NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev. 2010;62:650-666.
25. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62:12-27.
26. Bebok Z, Collawn JF, Wakefield J, et al. Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol. 2005;569(Pt 2):601-615.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[delta][delta]CT method. Methods. 2001;25:402-408.
28. Yang W, Peters JI, Williams RO. Inhaled nanoparticles-a current review. Int J Pharm. 2008;356:239-247.
29. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007;15:2070-2079.
30. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8:129-138.
31. Brissault B, Leborgne C, Guis C, Danos O, Cheradame H, Kichler A. Linear topology confers in vivo gene transfer activity to polyethylenimines. Bioconjug Chem. 2006;17:759-765.
32. Katas H, Alpar HO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release. 2006;115:216-225.
33. de Raad M, Teunissen EA, Lelieveld D, Egan DA, Mastrobattista E. High-content screening of peptide-based non-viral gene delivery systems. J Control Release. 2012;158:433-442.
34. Hibbitts A, Lieggi N, McCabe O, et al. Screening of siRNA nanoparticles for delivery to airway epithelial cells using high content analysis. Ther Deliv. 2011;2:987-999.
35. Laroui H, Theiss AL, Yan Y, et al. Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon. Biomaterials. 2011;32:1218-1228.
36. Wang J, Feng SS, Wang S, Chen ZY. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm. 2010;400:194-200.
37. Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm. 2011;77:438-449.
38. Gautam A, Densmore CL, Xu B, Waldrep JC. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther. 2000;2:63-70.
39. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537-541.
40. Castanotto D, Sakurai K, Lingeman R, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res. 2007;35:5154-5164.
41. Conese M, Ascenzioni F, Boyd AC, et al. Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros. 2011;10:S114-S128.